XOLAIR 150mg price in UAE

Overview

Welcome to Dwaey, specifically on XOLAIR 150mg Injection/Powder for page.
This medicine contains an important and useful components, as it consists of Omalizumab.
XOLAIR 150mg is available in the market in concentration 150mg/Vial and in the form of Injection/Powder for.

NOVARTIS PHARMA AG is the producer of XOLAIR 150mg and it is imported from SWITZERLAND, The most popular alternatives of XOLAIR 150mg are listed downward .

Mode Of Action

Omalizumab is an IgG monoclonal antibody (recombinant DNA-derived) which inhibits IgE binding to the high-affinity IgE receptor on mast cells and basophils.

Indication

Severe allergic asthma

Precaution

Not intended for treatment of acute asthma exacerbations, acute bronchospasm or status asthmaticus. Patient at risk of parasitic infections. May increase risk of malignancy. Delayed onset of anaphylaxis, it usually occurs 2 hr after admin but may also occur up to 4 days to >1 yr after initiation of regular treatment. Avoid abrupt withdrawal of corticosteroid therapy. Renal and hepatic impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor for signs and symptoms of anaphylaxis, infections. Lactation: Unknown if distributed into breast milk; use caution

Side Effects

>10% Injection site reactions (45%)
Viral infections (23%)
URI (20%)
Sinusitis (16%)
Headache (15%)
Pharyngitis (11%) 1-10% Pain (7%)
Arthralgia (8%)
Fracture (2%)
Fatigue (3%)
Dermatitis (2%)
Arm pain (4%)
Leg pain (4%)
Dizziness (3%)
Earache (2%)
Pruritus (2%)
Nasopharyngitis (3%)
Pyrexia (3%)
Upper abdominal pain (3%)
Pharyngitis streptococcal (3%)
Otitis media (3%)
Viral gastroenteritis (3%)
Epistaxis (3%) <1% Alopecia
Edema
Anaphylaxis
Bronchitis
Urticaria Potentially Fatal: Anaphylactic reactions including bronchospasm
hypotension
syncope
dyspnoea and/or angioedema of the throat or tongue.

Contra indication

Previous severe hypersensitivity reaction, acute bronchospasm, status asthmaticus.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Cytochrome P-450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of omalizumab; thus, there is little potential for drug-drug interactions. No formal drug or vaccine interaction studies have been performed with Omalizumab. There is no pharmacological reason to expect that commonly prescribed medications used in the treatment of asthma will interact with omalizumab. In clinical studies, Omalizumab was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short- and long-acting beta-agonists, leukotriene modifiers, theophyllines and oral antihistamines. There was no indication that the safety of Omalizumab was altered with these other commonly used asthma medications. Limited data are available on the use of Xolair in combination with specific immunotherapy (hyposensitisation therapy). Omalizumab may indirectly reduce the efficacy of medicinal products for the treatment of helminthic or other parasitic infections. Incompatibilities: Omalizumab should not be mixed with any medication or diluents other than water for injections.